Abulafia, A. S., Al-Ali, H. K., Andreasson, B., Angona, A., Ayala, R., Bang, S., . . . Kawashima, J. (2023). Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. The Lancet, 401(10373), 269-280. https://doi.org/10.1016/S0140-6736(22)02036-0

Abulafia, Adi Shacham, et al. "Momelotinib Versus Danazol in Symptomatic Patients with Anaemia and Myelofibrosis (MOMENTUM): Results from an International, Double-blind, Randomised, Controlled, Phase 3 Study." The Lancet 401, no. 10373 (2023): 269-280. https://doi.org/10.1016/S0140-6736(22)02036-0.

Abulafia, Adi Shacham, et al. "Momelotinib Versus Danazol in Symptomatic Patients with Anaemia and Myelofibrosis (MOMENTUM): Results from an International, Double-blind, Randomised, Controlled, Phase 3 Study." The Lancet, vol. 401, no. 10373, 2023, pp. 269-280, https://doi.org/10.1016/S0140-6736(22)02036-0.